Background
==========

Local anaesthesia is a common requirement for the performance of most dental procedures. The market offers many types of anaesthetics, but the greatest difference between them is the addition of vasoconstrictor agents. Some authors state that plain anaesthetics do not provide sufficient anaesthesia \[[@b1-medscimonit-20-393]--[@b3-medscimonit-20-393]\]. Vasoconstrictor agents have many advantages, such as delaying the absorption of local anaesthetics, increasing patient welfare due to the lower doses of anaesthetic required, diminishing potential toxic risk, and providing bleeding control \[[@b4-medscimonit-20-393]\]. Despite these benefits, its use has been limited due to fear of systemic absorption and the induction of adverse effects in cardiac compromised patients; it has sometimes been controversial \[[@b5-medscimonit-20-393]\]. However pain, stress, and fear are also responsible for the systemic liberation of endogenous catecholamines that can cause an autonomic response, such as provoking acute arrhythmias \[[@b6-medscimonit-20-393]\]. It should be noted that epinephrine released endogenously is a higher dose than that used in dental anaesthesia \[[@b7-medscimonit-20-393]--[@b9-medscimonit-20-393]\].

According to American Heart Association (AHA) and American Dental Association (ADA) guidelines, there is no contraindication to using a vasoconstrictor agent when administrated carefully and with preliminary aspiration \[[@b10-medscimonit-20-393]\]. The maximum dose of epinephrine in local anaesthesia for a healthy subject is 0.2 mg, though this can be lowered to 0.04 mg if patient has severe cardiovascular disease (ASA III and IV) \[[@b11-medscimonit-20-393]\]. Therefore, the aim of this study was to review the literature to assess any scientific basis for the limited use of dental anaesthesia with a vasoconstrictor agent in cardiovascular compromised patients.

Material and Methods
====================

On June 13^th^, 2013, a comprehensive database search was executed with the use of Medline (PubMed), ISI Web of Science, and Cochrane. No language frame was used. Only publications from the last 15 years were considered.

Search equations are presented in [Table 1](#t1-medscimonit-20-393){ref-type="table"}. To correctly translate the equation for other databases, the help of a senior librarian was obtained. The titles and abstracts that were found with an electronic search were screened and evaluated by 2 observers according to inclusion and exclusion criteria ([Table 2](#t2-medscimonit-20-393){ref-type="table"}). Studies that did not meet the defined criteria were excluded from further evaluation. Any discrepancies in the selection were settled through discussion. A prisma flow diagram illustrates the search and evaluation process ([Figure 1](#f1-medscimonit-20-393){ref-type="fig"}).

To provide reliable evidence, a critical appraisal of all included articles was carried out. The criteria for this purpose were applied from the "Methods Guide for Comparative Effectiveness Reviews" created by the American Agency for Healthcare Research and Quality \[[@b12-medscimonit-20-393]\]. The overall judgement was assessed as high or unclear risk, when 1 or more key domains was assessed as high or unclear. A low-risk judgement was formed when all key domains were at "low risk". This review was registered in "PROSPERO International prospective register of systematic reviews" as CRD42013004928.

Results
=======

Of the 294 articles initially found, an automatic rejection of duplicates in the EndNote X5 reference manager resulted in 138 articles. After screening the abstracts, 100 articles were excluded. Eligibility verification of full-text articles resulted in the final inclusion of 11 papers.

Six randomized clinical trials (RCT) and 5 controlled clinical trials (CCT) with no randomization met the inclusion criteria across all studies.

The risk of bias assessment revealed that all RCTs were low risk. Among CCTs, 2 papers had unclear risk and 3 had low risk. More detailed information is presented in [Table 3](#t3-medscimonit-20-393){ref-type="table"}.

The total number of patients was 567. Seven patients were excluded, 1 due to missing documentation (Elad et al.) and 6 due to motion artefacts during ECG (Neves et al.). Demographic data are presented in [Table 4](#t4-medscimonit-20-393){ref-type="table"}.

Among all of the included patients, the most frequent underlying pathology was hypertension. Other conditions are presented in [Figure 2](#f2-medscimonit-20-393){ref-type="fig"}. When 1 patient was related to 2 or more categories, it was assigned to each relevant group.

Only 3 authors reported the occurrence of any comorbid disease \[[@b16-medscimonit-20-393],[@b18-medscimonit-20-393],[@b21-medscimonit-20-393]\]. Neves et al. had 24 diabetic patients. Silvestre et al. had 27 with dyslipidemia and some with diabetes and stroke histories, but the exact number cannot be extracted. Additionally, Torres-Lagares et al. reported 10 more patients with different comorbidities.

The most frequently used anaesthesia was lidocaine at 2%. Three studies showed the use of articaine \[[@b14-medscimonit-20-393],[@b18-medscimonit-20-393],[@b21-medscimonit-20-393]\] and 3 mepivacaine \[[@b13-medscimonit-20-393],[@b18-medscimonit-20-393],[@b21-medscimonit-20-393]\]. The most commonly used vasoconstrictor was adrenaline (1:100000). One author reported premedication usage before the procedure. A control group appeared in 6 studies. The doses applied varied between from 1.8 to 6.9 ml ([Table 5](#t5-medscimonit-20-393){ref-type="table"}).

Among 560 patients after the administration of a local anaesthetic, 87 complications occurred. The most frequent complication was arrhythmia. Asymptomatic ischaemic changes were seen in 3 patients. One case of transient local neuropathy was noted ([Table 5](#t5-medscimonit-20-393){ref-type="table"}). No severe adverse clinical effects were reported.

Discussion
==========

A mean age of over 50, being male, and the presence of comorbid disease may provide a representative group. Other increased levels of evidence and low risk of bias in the included articles could be sufficient evidence for clinical decisions to be made.

The overall complication rate across studies was 15.5%. The highest proportion of complication (43.6%) was reported by Middlehurst et al. with noradrenaline (1:50000) + vasopressin 0.25 IU/ml. Additionally, midazolam was administrated as a premedication in 1 of the study groups. This high complication rate could result from the monitoring method used. Middlehurst et al. counted and analysed ECG waves (QRS complexes) from the sedation to recovery period. However, 2.7% of waves from LNEV and 5.7% from the LNEV+M group were found to be clinically significant \[[@b15-medscimonit-20-393]\]. It should also be noted that the anaesthesia scheme presented by Middlehurst et al. is not the most commonly used method in dental practice. Excluding this study from analysis due to inability to define the number of patients with clinically significant complications, the overall complication rate decreases to 8.75%.

Moreover, the transient local neuropathy reported in the Elad et al. study cannot be related to the presence of vasoconstrictor agents. Furthermore, a temporal analysis of the ischaemic changes reveals that they were not related to timing of the LA.

Neves et al. reported that 41.2% arrhythmias occurred during the procedure and the frequency of arrhythmias in a group with/without vasoconstrictor agents did not reveal a significant difference. Interestingly, arrhythmias have been reported in 37.5% of healthy patients who undergo multiple dental extractions under a local anaesthetic with a vasopressor agent \[[@b22-medscimonit-20-393]\]. In the Neves et al. study it was impossible to extract data about pre-anaesthesia ECG records. Therefore, the aforementioned data cannot be interpreted as stemming from the use of a vasoconstrictor agent. Another complication (ST-segment depression) occurred more than 2 hours after the procedure was completed. Additionally, complications reported by Blinder et al. took place 2 hours after the dental procedure. This relatively long time period is clearly not enough to establish a direct relationship between the vasoconstrictor agent and ECG records.

Among all complications, only 10 may be directly related to the use local anaesthesia. It is noteworthy that 40% appeared after the administration of anaesthesia without vasoconstrictor agents. No severe adverse clinical effects were noted in the analysed studies.

Conclusions
===========

1.  The most frequent complications in cardiovascular compromised patients after dental local anaesthesia with vasoconstrictor agent were disclosed in ECG arrhythmias.

2.  The range of diagnostic criteria complication frequency depends on application by different authors and ranges from 0% to 50%.

3.  A major part of the disclosed arrhythmias were clinically insignificant.

4.  The use of ≤4 ampules of lignocaine with epinephrine 1:100000 as a dental anaesthetic seems to be relatively safe for cardiovascular compromised patients.

5.  During the application of higher doses of anaesthesia or a higher concentration of an anaesthetic agent in cardiovascular compromised patients, ECG monitoring should be considered due to insufficient evidence of the safety of higher dosage use.

**Source of support:** Self financing
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###### 

Search equations.

  ---------------------------------------------------------------------------------------------------
  "Anesthesia, Dental \[MeSH Terms\] AND Cardiovascular Diseases \[MeSH Terms\]" -- Clinical Trials
  "Anesthesia, Dental \[MeSH Terms\] AND Hypertension \[MeSH Terms\]"
  "Anesthesia, Dental \[MeSH Terms\] AND Myocardial Ischemia \[MeSH Terms\]"
  "Anesthesia, Dental \[MeSH Terms\] AND Heart Arrest \[MeSH Terms\]"
  "Anesthesia, Dental \[MeSH Terms\] AND Cardiomyopathies \[MeSH Terms\]"
  "Anesthesia, Dental \[MeSH Terms\] AND Arrhythmias, Cardiac \[MeSH Terms\]"
  "Anesthesia, Dental \[MeSH Terms\] AND Heart Valve Diseases \[Mesh\]"
  ---------------------------------------------------------------------------------------------------

###### 

Inclusion and exclusion criteria.

  Inclusion criteria                                                                                                                                                                                                                                             Exclusion criteria
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  -- No language limit-- Publications from last 15 years-- Only human studies-- Clearly defined dose of vasoconstrictor agent--Testing at least one parameter (pressure, heart rate, saturation) or occurrence of at least one cardiac incident (complication)   -- No authors-- Animal studies-- *In vitro* studies

###### 

Risk of bias assessment.

  Randomized clinical trails   Controlled clinical trails                                                                    
  ---------------------------- ---------------------------- ---- ---- ---- ---- ---- ------------------- ---- ---- ---- ---- ----
  Selection bias               \+                           \+   \+   \+   \+   \+   Selection bias      \+   \+   \+   \+   \+
  Performance bias             \+                           \+   \+   \+   \+   \+   Performance bias    \+   \+   \+   \+   \+
  Attrition bias               \+                           \+   \+   \+   \+   \+   Attrition bias      \+   \+   \+   \+   \+
  Detection bias               \+                           \+   \+   \+   \+   \+   Detection bias      ?    ?    \+   \+   \+
  Reporting bias               \+                           \+   \+   \+   \+   \+   Reporting bias      \+   \+   \+   \+   \+
  Overall judgement            \+                           \+   \+   \+   \+   \+   Overall judgement   ?    ?    \+   \+   \+

\+ Low risk of bias; − high risk of bias; ? unclear risk of bias.

###### 

Demographic data.

  Total number of patients   Mean age     Gender       Study                                                          
  -------------------------- ------------ ------------ -------------------------------------------------------------- --------------------------
  **40**                                  66           M 23 F 17                                                      Blinder D. et al.
                                                                                                                      
  **60**                     Pre-HTN 10   52.6±11.07   M 32 F28                                                       Chaudhry S. et al.
  HTN-1 10                   49.33±5.85                                                                               
  HTN-2 10                   59.16±12.0                                                                               
  NT 30                      43±11.04                                                                                 
                                                                                                                      
  **54**                     ME 27        58±7.98      M 34 F 20                                                      Conrado V.C.L.S. et al.
  PM 27                      55.3±8.57                                                                                
                                                                                                                      
  **49**                     AE 25        61.8±10.6    M 39 F11[\*](#tfn2-medscimonit-20-393){ref-type="table-fn"}    Elad S. et al.
  LE 24                      60.4±11                                                                                  
                                                                                                                      
  **59**                     LE 28        40.3±10.9                                                                   Laragnoit A.B. et al.
  PL 31                      42.2±10.3    --                                                                          
                                                                                                                      
  **56**                     LE 27        58.7±8.8     M 51 F 11[\*](#tfn2-medscimonit-20-393){ref-type="table-fn"}   Neves R.S. et al.
  PL 29                                                                                                               
                                                                                                                      
  **27**                                  53±15.25     M 16 F 11                                                      Niwa H. et al.
                                                                                                                      
  **75**                     LNEV 50      58.3±11.0    M 56 F 19                                                      Middlehurst R.J. et al.
  LNEV+M 25                  57.7±13.6                                                                                
                                                                                                                      
  **33**                     LE 14        50.1±11.7    M 13 F 20                                                      Ogunlewe M.O. et al.
  PL19                                                                                                                
                                                                                                                      
  **97**                                  60.45±9.60   M 33 F 64                                                      Silvestre F.J. et al.
                                                                                                                      
  **10**                                  63±12.5      --                                                             Torres-Lagares D. et al.

Before exclusion. LE -- lidocaine with epinephrine; PL -- (plain) lidocaine; ME -- mepivacaine with epinephrine; PM -- (plain)mepivacaine; AE -- articaine with epinephrine; LNEV -- lidocaine with norepinephrine and vasopressin; M -- midazolam; Pre-HTN -- pre-hypertension; HTN-1 -- hypertension 1^st^ stage; HTN-2 -- hypertension 2^nd^ stage; NT -- normotensive patients.

###### 

Comparison of complication events.

  Anaesthetic                                                    Dose of anaesthesia           Type of complication                   Percent of patients   Study
  -------------------------------------------------------------- ----------------------------- -------------------------------------- --------------------- --------------------------
  2% lidocaine with 1:100,000 epinephrine                        5.4 ml or less                Arrhythmia                             15%                   Blinder D. et al.
  ST-segment depression                                          2.5%                                                                                       
  Tachycardia, increased HR                                      20%                                                                                        
  2% lignocaine with 1:100,000 epinephrine                       3.6 ml                        --                                     --                    Chaudhry S. et al.
  2% mepivacaine with 1:100,000 epinephrine                      1.89 cartridges               ST-segment depression                  11,1%                 Conrado V.C.L.S. et al.
  3% mepivacaine without vasoconstrictor                         1.56 cartridges               --                                     --                    
  Articaine 4% and adrenalin 1:200,000                           1.8 ml                        Asymptomatic ischaemic changes (EKG)   8%                    Elad S. et al.
  Lidocaine 2% and adrenalin 1:100,000                           1.8 ml                        Transient local neuropathy             4.2%                  
  Asymptomatic ischaemic changes (EKG)                           4.2%                                                                                       
  2% lidocaine with epinephrine 1: 100,000                       1.8 ml                        --                                     --                    Laragnoit A.B. et al.
  2% lidocaine                                                   5.4 ml for 75% of the cases                                                                
  2% lidocaine and 1:100,000 epinephrine                         1.8--3.6 ml                   ST-segment depression                  14.8%                 Neves R.S. et al.
  Arrhythmia                                                     25.9%                                                                                      
  2% lidocaine without epinephrine                               1.8--3.6 ml                   ST-segment depression                  20.7%                 
  Arrhythmia                                                     34.5%                                                                                      
  2% lidocaine with 1:80,000 epinephrine                         1.8 ml                        --                                     --                    Niwa H. et al.
  Lidocaine 2%, noradrenaline 1:50,000, vasopressin 0.25 IU/mL   LNEV: 4.9±2.0 ml              Dysrhythmia                            50%                   Middlehurst R.J. et al.
  LNEV+M: 5.5±1.4 ml                                             Dysrhythmia                   52%                                                          
  2% lignocaine with 1:80 000 adrenaline                         3.6 ml                        --                                     --                    Ogunlewe M.O. et al.
  2% lignocaine                                                                                                                                             
  4% articaine with epinephrine 1: 200,000                       1.8--5.4 ml                   --                                     --                    Silvestre F.J. et al.
  3% mepivacaine                                                                                                                                            
  Mepivacaine 30 mg without epinephrine                          3.6 ml                        --                                     --                    Torres-Lagares D. et al.
  Articaine 40 mg with epinephrine 0.5mg%                                                                                                                   
  Articaine 40 mg with epinephrine 1 mg%                                                                                                                    
  Mepivacaine 20 mg with epinephrine 1 mg%                                                                                                                  
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